These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22470118)

  • 1. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
    Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
    Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
    mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
    Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
    Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?
    Mohapatra PR
    Am J Respir Crit Care Med; 2009 Oct; 180(7):686; author reply 686-7. PubMed ID: 19762595
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
    Kjellsson MC; Via LE; Goh A; Weiner D; Low KM; Kern S; Pillai G; Barry CE; Dartois V
    Antimicrob Agents Chemother; 2012 Jan; 56(1):446-57. PubMed ID: 21986820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
    Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
    Weiner M; Burman W; Luo CC; Peloquin CA; Engle M; Goldberg S; Agarwal V; Vernon A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2861-6. PubMed ID: 17517835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
    Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
    mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Robert J; Jarlier V
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
    Dooley K; Flexner C; Hackman J; Peloquin CA; Nuermberger E; Chaisson RE; Dorman SE
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4037-42. PubMed ID: 18765687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
    Dorman SE; Johnson JL; Goldberg S; Muzanye G; Padayatchi N; Bozeman L; Heilig CM; Bernardo J; Choudhri S; Grosset JH; Guy E; Guyadeen P; Leus MC; Maltas G; Menzies D; Nuermberger EL; Villarino M; Vernon A; Chaisson RE;
    Am J Respir Crit Care Med; 2009 Aug; 180(3):273-80. PubMed ID: 19406981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
    Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
    Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.